The purpose of this research study is to see if a study drug called Tocilizumab will, when
given with standard anti-rejection medicines, lead to better heart transplantation outcomes
at 1 year after the transplant. Specifically, the investigators will evaluate whether taking
tocilizumab leads to less rejection, less development of unwanted antibodies, and better
heart function.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)